News

Liquidia Technologies, Inc.: Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerabil ...

Boralex Inc.: Boralex reports second quarter operating income comparable to 2024 and actively pursue its development and construction activities

Boralex Inc. ("Boralex" or the "Corporation") (TSX: BLX) is pleased to report its results for the second quarter of 2025. HighlightsFinancial results Lower ...